Galliprant® (grapiprant tablets) is a first-in-class prostaglandin receptor antagonist (PRA), a non-COX inhibiting NSAID.
- It specifically targets the EP4 receptor, the primary mediator of canine OA pain and inflammation1
- Galliprant’s mode of action targets canine osteoarthritis (OA) pain and inflammation while reducing the impact on GI, kidney and liver homeostasis1,2*
- There are no labelled requirements for serum biochemical evaluation, so veterinarians are allowed flexibility in appropriate long-term monitoring*
- Most dogs can be dosed once a day with a whole or half tablet**
* If Galliprant is used long-term, appropriate monitoring is recommended.
** Dogs weighing
less than 8lbs cannot be accurately dosed.
Dog owners may not associate early signs of OA with evidence of pain. Veterinarians may consider a Galliprant
trial period to assess improvement and help owners recognize the benefit of treating OA pain and
inflammation.
For more information, please visit: galliprantvet.com
INDICATION
Galliprant (grapiprant tablets) is an NSAID indicated for the control of pain and inflammation associated with osteoarthritis in dogs.
IMPORTANT SAFETY INFORMATION
Not for use in humans. For use in dogs only. Keep this and all medications out of reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. Do not use in dogs that have a hypersensitivity to grapiprant. If Galliprant is used long term, appropriate monitoring is recommended. Concomitant use of Galliprant with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8lbs (3.6kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. The most common adverse reactions were vomiting, diarrhea, decreased appetite, and lethargy.
Click here for full prescribing information.1. Kirkby Shaw K, Rausch-Derra LC, Rhodes L. Grapiprant: an EP4 prostaglandin receptor antagonist
and novel therapy for pain and inflammation. Vet Med Sci. 2016;2:3-9.
2. Rausch-Derra LC, Huebner M, Rhodes L. Evaluation of the safety of long-term, daily oral administration of
grapiprant, a novel drug for treatment of osteoarthritis pain and inflammation, in healthy dogs.